Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADRO NASDAQ:EVFM NASDAQ:LXRX NASDAQ:OSMT NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADROAduro Biotech$10.93$4.51▼$20.20$236.61M0.4162,237 shs171,500 shsEVFMEvofem Biosciences$0.02-1.9%$0.01$0.01▼$0.02$1.80M-1.11427,601 shs766,939 shsLXRXLexicon Pharmaceuticals$1.12-2.6%$1.13$0.28▼$2.18$417.91M1.261.56 million shs1.70 million shsOSMTOsmotica Pharmaceuticals$1.16$0.98▼$4.95$69.47M2.34396,682 shs296,500 shsSNDXSyndax Pharmaceuticals$15.84+1.9%$13.04$8.58▼$22.50$1.34B0.721.88 million shs2.08 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADROAduro Biotech0.00%0.00%0.00%0.00%0.00%EVFMEvofem Biosciences-1.94%+55.10%+61.70%+58.33%+67.03%LXRXLexicon Pharmaceuticals-2.61%+3.70%-9.68%+55.43%-34.12%OSMTOsmotica Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SNDXSyndax Pharmaceuticals+1.86%-3.00%+0.64%+64.32%-17.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADROAduro Biotech$10.93$4.51▼$20.20$236.61M0.4162,237 shs171,500 shsEVFMEvofem Biosciences$0.02-1.9%$0.01$0.01▼$0.02$1.80M-1.11427,601 shs766,939 shsLXRXLexicon Pharmaceuticals$1.12-2.6%$1.13$0.28▼$2.18$417.91M1.261.56 million shs1.70 million shsOSMTOsmotica Pharmaceuticals$1.16$0.98▼$4.95$69.47M2.34396,682 shs296,500 shsSNDXSyndax Pharmaceuticals$15.84+1.9%$13.04$8.58▼$22.50$1.34B0.721.88 million shs2.08 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADROAduro Biotech0.00%0.00%0.00%0.00%0.00%EVFMEvofem Biosciences-1.94%+55.10%+61.70%+58.33%+67.03%LXRXLexicon Pharmaceuticals-2.61%+3.70%-9.68%+55.43%-34.12%OSMTOsmotica Pharmaceuticals0.00%0.00%0.00%0.00%0.00%SNDXSyndax Pharmaceuticals+1.86%-3.00%+0.64%+64.32%-17.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADROAduro Biotech 0.00N/AN/AN/AEVFMEvofem Biosciences 0.00N/AN/AN/ALXRXLexicon Pharmaceuticals 2.50Moderate Buy$3.23187.95% UpsideOSMTOsmotica Pharmaceuticals 0.00N/AN/AN/ASNDXSyndax Pharmaceuticals 3.00Buy$39.22147.62% UpsideCurrent Analyst Ratings BreakdownLatest LXRX, SNDX, EVFM, ADRO, and OSMT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025SNDXSyndax PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.009/5/2025SNDXSyndax PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $24.009/4/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$34.009/2/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/7/2025LXRXLexicon PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.20 ➝ $1.908/6/2025SNDXSyndax PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/5/2025SNDXSyndax PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$46.00 ➝ $51.008/5/2025SNDXSyndax PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$43.00 ➝ $56.007/15/2025SNDXSyndax PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$37.00 ➝ $35.007/10/2025SNDXSyndax PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.006/24/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADROAduro Biotech$17.26M0.00N/AN/A$4.07 per share0.00EVFMEvofem Biosciences$11.39M0.16N/AN/A($2.64) per share-0.01LXRXLexicon Pharmaceuticals$31.08M13.10N/AN/A$0.40 per share2.80OSMTOsmotica Pharmaceuticals$177.88M0.00N/A1.00$1.50 per share0.00SNDXSyndax Pharmaceuticals$23.68M57.62N/AN/A$3.38 per share4.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADROAduro Biotech-$82.37M-$5.15N/AN/AN/A-230.92%-101.73%-22.35%N/AEVFMEvofem Biosciences$52.98M-$0.07N/A∞N/A-46.42%-91.97%-61.93%N/ALXRXLexicon Pharmaceuticals-$200.40M-$0.33N/AN/AN/A-206.43%-83.63%-42.22%11/11/2025 (Estimated)OSMTOsmotica Pharmaceuticals-$79.59M-$1.59N/AN/AN/A-138.76%-81.23%-20.97%N/ASNDXSyndax Pharmaceuticals-$318.76M-$3.89N/AN/AN/A-428.48%-130.47%-56.12%11/4/2025 (Estimated)Latest LXRX, SNDX, EVFM, ADRO, and OSMT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025LXRXLexicon Pharmaceuticals-$0.08$0.01+$0.09$0.01$4.87 million$28.87 million8/4/2025Q2 2025SNDXSyndax Pharmaceuticals-$1.01-$0.83+$0.18-$0.83$26.64 million$37.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADROAduro BiotechN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AOSMTOsmotica PharmaceuticalsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADROAduro BiotechN/A8.918.91EVFMEvofem BiosciencesN/A0.110.09LXRXLexicon Pharmaceuticals0.434.164.16OSMTOsmotica PharmaceuticalsN/A0.430.42SNDXSyndax Pharmaceuticals2.064.714.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADROAduro Biotech49.93%EVFMEvofem Biosciences0.22%LXRXLexicon Pharmaceuticals74.70%OSMTOsmotica Pharmaceuticals46.18%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADROAduro Biotech5.90%EVFMEvofem Biosciences0.01%LXRXLexicon Pharmaceuticals13.90%OSMTOsmotica Pharmaceuticals5.22%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADROAduro Biotech15216.21 millionN/AOptionableEVFMEvofem Biosciences120118.66 million113.12 millionNot OptionableLXRXLexicon Pharmaceuticals140363.40 million312.89 millionOptionableOSMTOsmotica Pharmaceuticals30262.59 million59.32 millionNot OptionableSNDXSyndax Pharmaceuticals11086.14 million82.61 millionOptionableLXRX, SNDX, EVFM, ADRO, and OSMT HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at Stifel NicolausSeptember 12, 2025 | marketbeat.comZimmer Partners LP Buys Shares of 213,159 Syndax Pharmaceuticals, Inc. $SNDXSeptember 11, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. $SNDX Shares Bought by Exome Asset Management LLCSeptember 11, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Coverage Initiated at Stifel NicolausSeptember 11, 2025 | americanbankingnews.comInsider Selling: Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 157,307 Shares of StockSeptember 10, 2025 | marketbeat.comSyndax resumed with Buy at Stifel on newly launched drugsSeptember 10, 2025 | msn.comPolar Asset Management Partners Inc. Purchases 21,630 Shares of Syndax Pharmaceuticals, Inc. $SNDXSeptember 9, 2025 | marketbeat.comStocks To Watch: Syndax Pharmaceuticals Sees Relative Strength Rating Jump To 84September 8, 2025 | msn.comSyndax Pharmaceuticals, Inc. $SNDX Shares Purchased by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $24.00September 8, 2025 | americanbankingnews.comGranahan Investment Management LLC Has $6.76 Million Stake in Syndax Pharmaceuticals, Inc. $SNDXSeptember 7, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Research Coverage Started at GuggenheimSeptember 7, 2025 | americanbankingnews.comGuggenheim Begins Coverage on Syndax Pharmaceuticals (NASDAQ:SNDX)September 6, 2025 | marketbeat.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.com59,210 Shares in Syndax Pharmaceuticals, Inc. $SNDX Purchased by Ieq Capital LLCSeptember 5, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Buy" by AnalystsSeptember 5, 2025 | marketbeat.comGuggenheim Initiates Coverage of Syndax Pharmaceuticals (SNDX) with Buy RecommendationSeptember 4, 2025 | msn.comDeep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)September 4, 2025 | benzinga.comSyndax Pharmaceuticals, Inc. $SNDX Shares Purchased by Palo Alto Investors LPSeptember 4, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. $SNDX Shares Purchased by Invesco Ltd.September 4, 2025 | marketbeat.comPoint72 Europe London LLP Takes Position in Syndax Pharmaceuticals, Inc. $SNDXSeptember 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXRX, SNDX, EVFM, ADRO, and OSMT Company DescriptionsAduro Biotech NASDAQ:ADROChinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.Evofem Biosciences NASDAQ:EVFM$0.02 0.00 (-1.94%) As of 09/15/2025 03:59 PM EasternEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.Lexicon Pharmaceuticals NASDAQ:LXRX$1.12 -0.03 (-2.61%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.14 +0.02 (+2.23%) As of 09:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Osmotica Pharmaceuticals NASDAQ:OSMTOsmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.Syndax Pharmaceuticals NASDAQ:SNDX$15.84 +0.29 (+1.86%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$16.00 +0.16 (+1.01%) As of 09:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
